Weight Drugs Pose Hidden Risks for Kids

Weight-loss medications such as Ozempic and Zepbound, while potent tools for combating childhood obesity, carry significant risks of nutritional deficiencies. A recent study revealed that approximately one in six children prescribed these GLP-1 medications were diagnosed with such deficiencies.

Vitamin D deficiency emerged as the most frequent issue, impacting over 12% of children within a year of starting GLP-1 treatment. Researchers emphasize the urgent need for proactive nutritional management, rather than reactive treatment of diagnosed deficiencies, to prevent harm during critical developmental stages.

Concerns are particularly high for nutrients like vitamin D, iron, and calcium, which are crucial during adolescence and can have lasting impacts on skeletal health and overall development. The study, analyzing insurance claims from over 100 million patients, found that only a small fraction of children received nutritional counseling post-prescription.

This lack of support is alarming, as nutritional deficiencies can lead to conditions like rickets and anemia. Less than a quarter of patients received any nutritional counseling within six months of beginning GLP-1 treatment, highlighting a significant gap in care for young patients using these powerful medications.